2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. RAD51
  5. RAD51 Inhibitor

RAD51 Inhibitor

RAD51 Inhibitors (18):

Cat. No. Product Name Effect Purity
  • HY-101462
    RAD51 Inhibitor B02
    		Inhibitor 99.91%
    RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.
  • HY-15317
    RI-1
    		Inhibitor 99.83%
    RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells.
  • HY-103710
    IBR2
    		Inhibitor 98.34%
    IBR2 is a potent and specific RAD51 inhibitor and inhibits RAD51-mediated DNA double-strand break repair. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, inhibits cancer cell growth and induces apoptosis.
  • HY-10206
    Amuvatinib
    		Inhibitor 99.47%
    Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
  • HY-126020
    Bractoppin
    		Inhibitor 99.70%
    Bractoppin is a potent and selective agent-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain (binding IC50: 74 nM). Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. Bractoppin preferentially inhibits BRCA1 tBRCT-dependent steps in the DNA damage response.
  • HY-150147
    CAM833
    		Inhibitor 99.79%
    CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis.
  • HY-122705
    RAD51-IN-1
    		Inhibitor 99.97%
    RAD51-IN-1, a derivative of  B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research.
  • HY-148183
    Homologous recombination-IN-1
    		Inhibitor 99.65%
    Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC50=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination.
  • HY-16904
    RI-2
    		Inhibitor 99.64%
    RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
  • HY-111887
    Emzadirib
    		Inhibitor 99.79%
    Emzadirib (RAD51-IN-2) is a RAD51 inhibitor extracted from patent WO2019/051465A1.
  • HY-126972A
    RI(dl)-2 TFA
    		Inhibitor 98.02%
    RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC50 of 11.1 μM. RI(dl)-2 TFA does not influence RAD51 binding to ssDNA and inhibits homologous recombination (HR) activity in human cells (IC50 of 3.0 μM).
  • HY-136604
    RAD51-IN-3
    		Inhibitor 99.24%
    RAD51-IN-3 is a Rad51 inhibitor extracted from patent WO2019051465A1, compound Example 66A.
  • HY-143736
    RAD51-IN-5
    		Inhibitor 98.87%
    RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3).
  • HY-143735
    RAD51-IN-4
    		Inhibitor
    RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12).
  • HY-143741
    RAD51-IN-7
    		Inhibitor
    RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71).
  • HY-10206A
    Amuvatinib hydrochloride
    		Inhibitor
    Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
  • HY-143737
    RAD51-IN-6
    		Inhibitor
    RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23).
  • HY-121693
    DIDS
    		Inhibitor
    DIDS is a potent RAD51 inhibitor. DIDS inhibits the RAD51-mediated homologous pairing and strand-exchange reactions. DIDS inhibits anion exchange and binding to the red blood cell membrane.